# A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

> **NCT01313663** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Lung Cancer, Small Cell

## Interventions

- **DRUG:** pazopanib
- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT01313663
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01313663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01313663, "A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01313663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*